Fierce Pharma November 8, 2023
A press release has landed Daiichi Sankyo in hot water in the U.K. Pharma’s self-regulatory body found Daiichi prejudiced patient safety by failing to reference a contraindication, leading it to conclude that the Japanese drugmaker had brought discredit on the industry.
The discredit stems from the opening line of a release about the cholesterol-lowering drugs Nilemdo and Nustendi receiving a reimbursement decision in the U.K. In the release, Daiichi said Nilemdo is “a novel, first‐in‐class, oral treatment which lowers cholesterol, and can be combined with other oral treatments to help lower cholesterol even further.”
That statement is true but, according to the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA), isn’t the whole truth. The problem? Nilemdo cannot be used...
Today's Sponsors
Today's Sponsor